Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
Full Year Results 2024
Watch Riad Mishlawi, CEO
Latest stories
Featured
Hikma to host meet the management and site visit in Columbus, Ohio
Press Release, Corporate
17 March 2025
- Inspiring women of Hikma - Meet Stephanie Haas, Senior Director, Head of Hikma Rx Procurement Story, Leadership 05 June 2025 Inspiring women of Hikma - Meet Stephanie Haas, Senior Director, Head of Hikma Rx Procurement
- Hikma launches Triamcinolone Acetonide Injectable Suspension, USP, in the US Press Release, Product 05 June 2025 Hikma launches Triamcinolone Acetonide Injectable Suspension, USP, in the US
- Fitch upgrades Hikma Pharmaceuticals PLC’s long-term issuer default rating to ‘BBB’, outlook stable Press Release, Corporate 29 May 2025 Fitch upgrades Hikma Pharmaceuticals PLC’s long-term issuer default rating to ‘BBB’, outlook stable
- Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection Press Release, Product 27 May 2025 Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
